Medicare Part D a boon for drug companies, House report says
Los Angeles Times, July 25, 2008
U.S. drug manufacturers are reaping a windfall from taxpayers because Medicare's privately administered prescription drug benefit program pays more than other government programs for the same medicines, according to a report from the House Committee on Oversight and Government Reform. The report found that taxpayers are paying up to 30% more for prescription drugs under Medicare's privatized Part D program for seniors and the disabled than under the government's Medicaid program for the poor. Committee Chairman Henry A. Waxman said he would introduce legislation to guarantee that federal taxpayers would not be charged higher prices under Medicare Part D than under Medicaid.
- CFO Exchange: Smartphones Poised to Disrupt Healthcare, Says Topol
- Consumerism Drives Healthcare Branding, Rebranding Efforts
- PA Ranks See 'Phenomenal Growth,' Lack of Diversity
- 3 Traits Personality Assessments Can't Reveal
- Antibiotic Overuse a 'Huge Threat' to Patient Safety, Says CDC
- CNO on Hospital Redesign: 'You Can't Over-Communicate'
- How Digital Strategy Shapes Patient Engagement at Boston Children's Hospital
- CHS Hacked, 4.5M Patient Records Compromised
- CFO Exchange: Healthcare Leaders Share 5 Innovative Ideas
- Carondelet to Pay $35M to Settle Fraud Allegations